Chantal M. Van Luijk
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Measurement of Tralokinumab Concentrations in Serum and Tear Fluid of Atopic Dermatitis Patients and the Relationship With Treatment Response and Ocular Surface Disease.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: February 23, 2025
Dupilumab-Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: November 20, 2024
Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitis.
Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Published: October 23, 2024
Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: August 24, 2023
Allogeneic Serum Eye Drops: A Randomized Clinical Trial to Evaluate the Clinical Effectiveness of Two Drop Sizes.
Journal: Ophthalmology and therapy
Published: August 02, 2023
Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile.
Journal: Ocular immunology and inflammation
Published: February 28, 2023
Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: January 11, 2023
Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis.
Journal: Allergy
Published: January 10, 2023
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease.
Journal: Clinical and translational allergy
Published: December 01, 2022
Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: October 17, 2022
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
Journal: Acta dermato-venereologica
Published: January 31, 2022
Last Updated: 09/26/2026